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Background: The role of nasal potential difference (NPD) measurement as a diagnostic test for cystic ﬁbrosis (CF) is a subject of global controversy
because of the lack of validation studies, clear reference values, and standardized protocols for diagnostic NPD.
Methods: To determine diagnostic NPD frequency, protocols, interpretation, and rater agreement, we surveyed the 18 NPD centres of the European
Cystic Fibrosis Society Diagnostic Network Working Group.
Results: Fifteen centres reported performing 373 diagnostic NPDs in 2012. Most use the CFF–TDN–SOP (67%) and the chloride-free + isoproterenol
response of the side with the largest response (47%) as diagnostic criteria and use centre-speciﬁc reference ranges. Rater agreement for ﬁve NPD
tracings – in general – was good, but poor in tracings with different responses between the two nostrils.
Conclusions: NPD is frequently used as a diagnostic and research tool for CF. Performance is highly standardized, centre-speciﬁc reference ranges are
established, and rater agreement – in general – is good. Centre-independent diagnostic criteria and reference ranges must be deﬁned by multicentre
validation studies to improve standardized interpretation for diagnostic use.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Nasal potential difference; Diagnosis☆ Data were partially presented at the ECFS Diagnostic Network Working Group meeting in Jerusalem/Israel, 14 February 2013.
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Nasal potential difference (NPD) measurement has been
developed as a research tool to investigate respiratory epithelial
function of the cystic fibrosis (CF) transmembrane regulator
(CFTR) protein in vivo [1]. NPD measures the transepithelial
bioelectric potential difference between ciliated epithelium in the
nostril and a subcutaneous electrode [1]. Sodium conductance is
assessed by perfusion with amiloride and CFTR function by
perfusion with a chloride-free solution and isoproterenol [1].
NPD has been used as a diagnostic test for CF since the late
1980s [2–5] and was accepted as a diagnostic procedure equal
to sweat chloride N60 mmol/l and/or detection of two
CF-causing mutations in 1998 in the Cystic Fibrosis Founda-
tion (CFF) consensus statement [6]. This consensus statement
highlighted the need for standardization, technical rigour, and
own reference ranges, especially for diagnostic use [6]. Over
time, variations in technique have been reported [7,8] resulting
in a high variability among centres [9] and even clinical
misdiagnosis [10]. For multicentre clinical and research trials,
a standard operating procedure (SOP) was established by the
CFF–Therapeutic Development Network (TDN) in 2004
[11,12] and has since been used in many clinical and research
trials [13]. In 2006, the European Cystic Fibrosis Society
(ECFS) Diagnostic Network Working Group (DNWG) con-
sensus report confirmed the role of NPD as a diagnostic tool for
CF [14]. This confirmation is in contrast to the CFF consensus
report from 2008 [15], which accepted NPD only as an
additional ancillary test because of the lack of validation
studies, clear reference values, and standardized protocols for
diagnostic NPD measurements [15]. These inconsistencies
between US and European diagnostic guidelines may lead to
different diagnoses being reached [16].
We performed a survey among NPD centres of the ECFS
DNWG to determine the frequency of diagnostic NPD and
protocols used. We also provided a series of NPD tracings and
asked investigators for their interpretation, from which we
assessed rater agreement.
2. Methods
A questionnaire was e-mailed to all 18 centres that participate
in the ECFS DNWG and are known to perform NPD. The survey
was carried out between November 2012 and March 2013.
The questionnaire consisted of three parts: (1) centre experience
and performance (number of NPD measurements in the preceding
12 months; mentioned as “in 2012”); (2) protocol used, diagnostic
assessment criteria, and reference range; and (3) interpretation of
five anonymised NPD tracings.
To test rater agreement, we chose five NPD tracings
(online supplement), which were performed in Giessen/Germany
according to the CFF–TDN–SOP and recorded as LabChart®
files (release 7.2; ADInstruments Ltd., Dunedin, New Zealand).
The tracings represent characteristic recordings for CF (tracing 1:
high negative basal potential difference (PD), large amiloride and
no chloride-free + isoproterenol response in both nostrils);
borderline (tracing 2: low negative basal PD, small amiloride andborderline chloride-free + isoproterenol response in both nostrils);
Non-CF (tracing 3: low negative basal PD, small amiloride and
large chloride-free + isoproterenol response in both nostrils); the
other two tracings demonstrated different responses between the
two nostrils: tracing 4 consisting of low negative basal PD, small
amiloride and no chloride-free + isoproterenol response, including
no ATP response in only one nostril, and tracing 5 consisting
of high negative basal PD, large amiloride and large chloride-
free + isoproterenol response only in one nostril, and ATP
response in both nostrils (details Table 1). Centres were asked to
open the anonymised files in LabChart® Reader (release 7.3.4;
ADInstruments Ltd., Dunedin, New Zealand), calculate the
relevant effects according to their own individualised approach,
and categorize the tracings into the following categories: (a) CF,
(b) Non-CF, (c) borderline, or (d) trace cannot be interpreted
(e.g. technically inacceptable tracings). The institutional review
board of the University of Giessen/Germany approved the use of
anonymised NPD tracings for this survey. Informed written
consent was obtained from each patient (≥18 years) and/or each
patient's parents or legal guardian.
Data are presented as median values and ranges. To test the
rater agreement of each tracing, a modified kappa test was
performed [17]. To test rater agreement for all five tracings, a
Fleiss kappa test was performed [18]. Kappa values can range
from −1 (complete disagreement) to +1 (perfect agreement)
and are interpreted by the degree of agreement: b0.40, poor;
0.40–0.75, good; and N0.75, excellent [18]. Statistical signifi-
cance was defined as p b 0.05.
3. Results
Fifteen NPD centres from 9 countries (Australia, Belgium (2
centres), Canada, France, Germany (5 centres), Great Britain (2
centres), Israel, Italy, Sweden) responded to the survey (response
rate 83%). In these centres the first NPD in each centre had been
performed between 1987 and 2010 (experience: median
14 years, range 2–26 years). All centres together reported 878
NPD measurements in 12 months preceding survey completion.
Diagnostic NPDs accounted for 42% (total number 373). The
number of NPD measurements (median 51, range 5–139) and
the percentage of diagnostic measurements (median 48%; range
17–100%) varied considerably among the centres (Fig. 1).
Diagnostic NPDs in relation to the national CF population in
2009 (based on the ECFS patient registry [19], the Australian CF
data registry [20] and the Canadian CF registry [21]) per year also
varied widely among countries (mean 1:58, range 1:5–1:282;
number of diagnostic NPDs per year per CF patient).
The centres most often used the CFF–TDN–SOP (67%),
followed by the ECFS–NPD–SOP (33%) and/or their own protocol
(7%). For diagnostic purposes, most centres interpreted the chloride-
free + isoproterenol response (47%). The Wilschanski ratio
(definition: e( response to chloride-free and isoproterenol/response to amiloride))
[22] and Sermet score (definition: −0.11 × response to chloride-
free and isoproterenol − 0.05 × response to amiloride) [23]
were used by three (20%) and two (13%) centres, respectively.
The other centres (20%) judged all of these criteria and the basal
PD together. Only 27% of the centres used an average of both
Table 1
Details of the provided NPD tracings (numbers in mV; Δ: response; Cl: chloride; CF: CF reference range; bold: CF range; scored by the centre of Giessen/Germany).
Criteria Tracing 1 Tracing 2 Tracing 3 Tracing 4 Tracing 5
Left Right Mean Left Right Mean Left Right Mean Left Right Mean Left Right Mean
Basal PD −41.6 −37.9 −6.8 −9.3 −21.2 −24.1 −13.3 −23.9 −27.9 −34.4
Δ Amiloride 24.7 25.7 5.6 7.7 15.7 15.4 9.7 20.1 25.2 26.2
Δ Clfree + iso
CF: N−7.7 mV [16]
9.0 5.5 7.3 −10.9 −8.4 −9.7 −26.1 −20.9 −23.5 −1.3 −11.5 −6.4 −31.5 −9.3 −20.
Δ ATP −1.3 −11.2 2.8 −5.7 −5.2 −9.9 −2.2 −14.0 −12.7 −4.1
Wilschanski score
CF: N0.7 [22]
1.4 1.2 1.3 0.14 0.34 0.23 0.18 0.27 0.22 0.87 0.56 0.65 0.30 0.71 0.47
Sermet score
CF: b0.27 [23]
−2.23 −1.88 −2.06 0.93 0.54 0.74 2.19 1.50 1.85 −0.34 0.26 −0.04 2.02 −0.31 0.85
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free + isoproterenol response (53%) for diagnostic interpretation;
fewer centres used both sides separately (13%) or the technically
better side (7%).
The reference ranges were highly centre specific (86%).
Most were based on centre-derived references, and cut-off
values for establishing a CF-diagnosis or to a borderline result
varied among the centres (Table 2).
Interpretations of all five NPD tracings showed in general a
good rater agreement. The agreement for typical CF (tracing 1)
and non-CF (tracing 3) tracings was excellent. For borderline
tracing (tracing 2) and subjects with different measurements
from two nostrils (tracing 4 and 5), the agreement ranged from
poor to good (Table 3).Centres
125
100
75
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Fig. 1. Number of NPDs per centre in 2012 (ordered by the number of diagnostic
NPD measurements).4. Discussion
Around 370 diagnostic NPDs are performed yearly in
Europe, Israel, Canada, and Australia among the ECFS DNWG
centres responding. Despite variability in protocols, assessment
criteria, and reference ranges rater agreement in general is
good, but poor in NPD with different responses between the
two nostrils across centres.
The high number of diagnostic NPDs underlies the clinical
need for further investigations in questionable cases. The exact
number of CF patients whose diagnosis is based only on NPD
as laboratory evidence for CFTR dysfunction is unknown and
not reported in any CF registry. NPD is, however, important in
equivocal cases to demonstrate a normal CFTR function and to
exclude CF [22,24]. The different numbers of NPD investiga-
tions among countries reflect different attitudes towards and
access to NPD. The number of diagnostic applications alone is
often less than 30 per centre per year, which is below a critical
number of sweat tests per year per centre (n = 50) demanded to
demonstrate adequate experience according to guidelines [25].
In most centres, the amount of research exceeds diagnostic
measurements, and research measurements are critical for
keeping rigourous records on use of this sophisticated method.
The procedure of a diagnostic NPD has become highly
standardized. All centres except one use the CFF–TDN–SOP
or the ECFS–NPD–SOP, which was recently developed by the
ECFS DNWG and ECFS Clinical Trials Network (CTN) for
diagnostic purposes and as outcome marker for clinical trials,
and serves as the SOP for an ongoing diagnostic ECFS
validation study within the ECFS DNWG. In contrast to theTable 2
Interpretation and inter-rater reliability for each provided NPD tracing.
Category CF Non-CF Borderline Cannot be interpreted kappa [18]
Tracing 1 15 0 0 0 1.000
Tracing 2 0 11 2 2 0.543
Tracing 3 0 14 1 0 0.867
Tracing 4 1 2 8 4 0.333
Tracing 5 0 12 3 0 0.657
Table 3
Reference ranges for different diagnostic criteria and diagnostic categories used
by the ECFS DNWG centres (cutoffs and mean ± SD; cursive: CFF–TDN
international dataset [29]).
Category
Diagnostic criteria CF Non-CF Reference SOP
Chloride-free +
isoproterenol
response
N−7.7 mV b−12 mV [16] CFF
N−6.62 mV b−6.62 mV [29] CFF
N−10 mV b−10 mV [24] Own
N−4 mV b−10 mV Centre specific ECFS
N−6 mV b−10 mV Centre specific ECFS
0.9 ± 3.6 mV −27.7 ± 14.6 mV [30] CFF
3 ± 6 mV −12 ± 7 mV [22] CFF
1.2 ± 3.9 −22.4 ± 13.1 mV [29] CFF
2.1 ± 3.8 mV −17.5 ± 12.0 mV Centre specific CFF
Wilschanski ratio
[22]
N0.70 b0.65 [22] CFF
N0.77 b0.72 Centre specific CFF
N0.85 b0.85 Centre specific CFF
Sermet score [23] N0.27 b0.27 [23]
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warming the solutions, uses a different catheter, and measures
on the floor of the nostril instead of under the inferior turbinate.
Studies have shown no significant differences with warming
solutions [26] nor location of measurement [27]. To date most
centres use the research CFF–TDN–SOP for diagnostic
purposes.
Neither SOP covers the interpretation of NPD. This can lead to
slight differences in calculating the mean PD at the end of a
perfusion period. For the CFF–TDN–SOP, the suggested
approach is to ascertain a steady-state voltage tracing for at
least 30 s or a maximal perfusion time of 5 min [12]. To account
for non-steady-state voltage tracings at the end of the maximal
perfusion time, Rowe et al. [12] recommend calculating the mean
PD for the final 10 s to represent a stable area. Another
suggestion is to calculate CFTR function based on the average
of both nostrils or only on the nostril with the largest response of
chloride-free + isoproterenol solution. Only 27% of the centres
calculates the average of both nostrils, which was established to
reduce variability between two measurements in one individual
[9]. Of all the centres, 47% uses the side with the largest response
of chloride-free + isoproterenol, which reflects the opinion that
for diagnostic issues, the best response represents the CFTR
function.
Despite a broad experience with the CFF–TDN–SOP,
universal assessment criteria and reference ranges for diag-
nostic use have not been defined. Knowles et al. [3] report the
chloride-free and isoproterenol response as the best discrim-
inator for CF and non-CF. Some authors have taken the
amiloride response into account for calculating scores [22,23].
In our survey, the majority of the centres relied on the absolute
chloride-free + isoproterenol response and only a minority on
the so-called Wilschanski ratio [22] or Sermet score [23] as the
diagnostic criteria for CF.Most centres have established centre-specific references and
use ranges that differ from published values [28], even with the
same SOP and same diagnostic criteria. This fact underlines the
need for a large and representative reference population (healthy
controls and CF patients) to calculate centre-independent
reference ranges, which is a challenge for each centre. Based on
the tracings send in for certification the CFF–TDN has published
ranges and diagnostic cut-offs including 144 non-CF and 135 CF
subjects from 54 operators and 29 centres (Table 3) [29]. This
approach to normative ranges could be biased by the anticipated
exclusion of borderline cases and tracings with different
responses between the two nostrils by the centres. It will be one
of the major goals of the ongoing ECFS–NPD–SOP validation
study to define the best centre-independent/universal diagnostic
criteria and reference range.
Despite the variability in SOPs, assessment criteria, and
reference ranges, the rater agreement in general was good and
excellent for typical CF and non-CF tracings. But rater agreement
for tracings with different responses between the two nostrils or
borderline patterns was much lower and for some tracings only
poor. Most centres recommend repeating NPD tracings with
different responses between the two nostrils, which is in agreement
with the recommendations of the 1998 CFF consensus statement
[6]. Other centres stated these tracings as “uninterpretable”, which
has not been addressed in previous discussions of NPD
measurements. Because most centres use the side with the highest
response and not the average, these tracings were evaluated as
insufficient evidence to support the diagnosis of CF. However
patients referred for NPD testing frequently have tracings with
different responses between the two nostrils or borderline patterns,
which can be difficult to interpret. In contrast to our survey, which
focused on tracings only, most of the centres interpret diagnostic
tracings in the context of the clinical picture. However
standardisation of interpretation and centre-independent refer-
ence ranges for diagnostic use are overlooked parts of NPD in the
past and are needed to avoid a scenario, where patients will be
diagnosed as CF at one and non-CF at another centre based on
different interpretations of the same NPD.5. Conclusions
The high number of diagnostic NPD measurements empha-
sizes the clinical need for a diagnostic tool in addition to sweat
chloride and genotyping to quantify CFTR function. Despite a
high standardization and a good rater agreement – in general – of
NPD, diagnostic criteria and reference ranges still need to be
defined across centres to improve interpretation of tracings with
different responses between the two nostrils or borderline
patterns. Validation studies like the ECFS–NPD–SOP validation
study could help to answer these important questions for
overcoming the differential appraisals of diagnostic NPD
among countries.Conﬂict of interest
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